You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
維亞生物(01873.HK)投資之生物醫藥公司Totient獲AbSci收購
阿思達克 06-16 11:06
維亞生物(01873.HK)投資孵化的生物醫藥公司Totient獲合成生物學公司AbSci收購。通過是次對Totient的收購,AbSci將爲其治療性蛋白設計和生物製造優化平臺增加新的抗體和靶標發現技術。

Totient已從逾5萬名患者中重建了4,500多種抗體,並運用其人工智能平臺鑑別和驗證了一系列具有治療潛力的抗體以及其相對應的靶標抗原。此技術與AbSci的高通量單細胞蛋白表達系統和檢測平臺形成了有效互補,可以快速、系統性地鑑別抗體序列。

維亞生物首席商務官及投資負責人戴(日含)表示,集團自2019年3月起採用「服務換股權(EFS)+現金」模式投資孵化Totient 。AbSci對Totient的收購,同時也進一步驗證了維亞EFS模式的可操作性。(ek/a)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account